接受曲妥珠单抗德曲妥珠单抗治疗的HER2阳性乳腺癌和软脑膜转移患者的持久反应。
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.
作者信息
Alder Laura, Trapani Dario, Bradbury Claire, Van Swearingen Amanda E D, Tolaney Sara M, Khasraw Mustafa, Anders Carey K, Lascola Christopher D, Hsu Liangge, Lin Nancy U, Sammons Sarah
机构信息
Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA.
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
出版信息
NPJ Breast Cancer. 2023 Mar 30;9(1):19. doi: 10.1038/s41523-023-00519-0.
Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.
软脑膜转移（LM）是HER2阳性转移性乳腺癌（MBC）的一种毁灭性并发症，目前尚无有效治疗方法。在一项针对8例接受过大量治疗的HER2阳性MBC且发生进展性LM的患者的病例系列研究中，所有8例患者（100%）均从曲妥珠单抗德鲁昔单抗（TDXd）中获得了临床益处，并且根据使用欧洲癌症研究与治疗组织/神经肿瘤疗效评估和反应标准（EORTC/RANO-LM）修订评分卡进行的正式神经放射学MRI解读，4例患者（50%）有客观部分缓解。TDXd在HER2阳性MBC和可能对TDXd敏感的实体瘤的LM中值得进一步研究。
Zotero 插件